NCT06487156View on ClinicalTrials.gov

A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RecruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

October 11, 2030

Study Completion Date

October 11, 2030

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Nivolumab + ipilimumab

As per product label

Trial Locations (1)

80131

RECRUITING

Istituto Nazionale Tumori - IRCCS Fondazione G.Pascale, Napoli

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY